RecruitingNCT05918523
A Long-Term Follow-Up Study of Participants Exposed to REACT
A Long-Term Follow-up Study of Participants Exposed to Renal Autologous Cell Therapy From Studies RMCL-002, REGEN-003, REGEN-004
Sponsor
Prokidney
Enrollment
80 participants
Start Date
Dec 11, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this study is to evaluate the long-term safety of up to two gelatin-hydrogel formulation REACT injections given 3 to 6 months apart and delivered percutaneously into same kidney on renal function in participants with chronic kidney disease (CKD).
Eligibility
Min Age: 30 YearsMax Age: 80 Years
Inclusion Criteria1
- The participant must have received gelatin-hydrogel formulation REACT in a previous trial (RMCL-002, REGEN-003, REGEN-004) for the treatment of chronic kidney disease and completed an end of study visit in their parent trial per protocol.
Exclusion Criteria1
- The participant did not receive REACT in a previous trial for the treatment of chronic kidney disease.
Interventions
BIOLOGICALRenal Autologous Cell Therapy (REACT)
No interventions in this trial
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05918523
Related Trials
Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus
NCT0659339212 locations
Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
NCT053181961 location
Improving Kidney Care in Type 2 Diabetes: A Study of Pharmacist Prescribing Versus Usual Care
NCT071694221 location
Home Hospital for Suddenly Ill Adults
NCT035242222 locations
Histopathological Analysis of Renal Biopsies With Dynamic Full-field Optical Coherence Tomography, a Comparison to Conventional Histopathological Findings for the Diagnosis of Either Acute Kidney Injury or Chronic Kidney Disease in Routine Practices (NEPHROCT)
NCT057282161 location